SCHEMBL1339641

SCHEMBL1339641

CCOC(=O)C(=NO)C(=O)c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.51
CES1 P23141 1/20 0.51
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAPT P10636 3/20 0.45
ALDH1A1 P00352 3/20 0.44
TSHR P16473 2/20 0.44
HPGD P15428 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NPC1 O15118 1/20 0.43
ELANE P08246 1/20 0.43
PARP1 P09874 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29697823 1.00 CES2 (0.51) CES2CES1LMNASMN1; SMN2POLB
SCHEMBL1339638 1.00 CES2 (0.51) CES2CES1LMNASMN1; SMN2POLB
SCHEMBL9954776 0.85 CES2 (0.61) CES2CES1LMNASMN1; SMN2POLB
SCHEMBL10442044 0.83 LMNA (0.52) CES2CES1LMNASMN1; SMN2POLB
SCHEMBL7978018 0.82 MAPT (0.49) CES2CES1LMNASMN1; SMN2TDP1
SCHEMBL7978024 0.82 MAPT (0.49) CES2CES1LMNASMN1; SMN2TDP1
SCHEMBL7988285 0.82 CES2 (0.58) CES2CES1LMNASMN1; SMN2TDP1
SCHEMBL7988288 0.82 CES2 (0.58) CES2CES1LMNASMN1; SMN2TDP1
SCHEMBL1968821 0.82 ALDH1A1 (0.61) CES2CES1LMNASMN1; SMN2MAPT
SCHEMBL19663921 0.82 ALDH1A1 (0.61) CES2CES1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063099-B2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-11-22 US disclosed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 EP disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
EP-2185512-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-05-19 EP disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 CES2 1485/4885CES1 1187/4885LMNA 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.